Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Tepotinib
Synonyms
Therapy Description

Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tepotinib Tepmetko EMD1214063|EMD-1214063|EMD 1214063|MSC2156119|MSC-2156119|MSC2156119J MET Inhibitor 59 Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02864992 Phase II Tepotinib Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT03940703 Phase II Osimertinib + Tepotinib Tepotinib A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | BEL 10
NCT01014936 Phase I Tepotinib First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors Completed USA 0
NCT05120960 Phase I Tepotinib Osimertinib + Tepotinib A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors Recruiting USA 0
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting NLD 0
NCT04739358 Phase Ib/II Tepotinib CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC Terminated USA 0


Additional content available in CKB BOOST